Amgen said its injectable version of Tepezza (teprotumumab) cleared a Phase 3 bar in thyroid eye disease, producing comparable efficacy to the infused version in a key study. The company’s updated readout arrives as Viridian Therapeutics prepares for an incoming competitive challenge after posting its own Phase 3 results. Tepezza has maintained a market-leading position, and injectable data could support broader treatment logistics and reinforce differentiation versus emerging alternatives. The report also notes analysts’ skepticism on the competitive standing versus rivals. Market participants will focus on whether Amgen can sustain prescription momentum as competitors move into late-stage readouts and potential label expansions.